Amgen (AMGN) Competitors $303.01 +5.08 (+1.71%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$302.98 -0.03 (-0.01%) As of 02/21/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AMGN vs. GILD, VRTX, REGN, ALNY, BIIB, UTHR, INCY, BMRN, NBIX, and EXELShould you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Amgen vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings. Does the MarketBeat Community believe in GILD or AMGN? Gilead Sciences received 927 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.83% of users gave Gilead Sciences an outperform vote while only 72.03% of users gave Amgen an outperform vote. CompanyUnderperformOutperformGilead SciencesOutperform Votes247776.83% Underperform Votes74723.17% AmgenOutperform Votes155072.03% Underperform Votes60227.97% Is GILD or AMGN a better dividend stock? Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 2.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.1%. Gilead Sciences pays out 832.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Does the media refer more to GILD or AMGN? In the previous week, Gilead Sciences had 12 more articles in the media than Amgen. MarketBeat recorded 69 mentions for Gilead Sciences and 57 mentions for Amgen. Amgen's average media sentiment score of 1.57 beat Gilead Sciences' score of 1.27 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 49 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 52 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals hold more shares of GILD or AMGN? 83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by insiders. Comparatively, 0.7% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, GILD or AMGN? Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$28.75B4.77$480M$0.37297.16Amgen$33.42B4.87$4.09B$7.5540.13 Do analysts recommend GILD or AMGN? Gilead Sciences presently has a consensus target price of $102.08, indicating a potential downside of 7.16%. Amgen has a consensus target price of $314.09, indicating a potential upside of 3.66%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 11 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.72Amgen 2 Sell rating(s) 10 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.46 Is GILD or AMGN more profitable? Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences1.67% 31.63% 10.38% Amgen 12.24%176.32%11.71% Which has more volatility & risk, GILD or AMGN? Gilead Sciences has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. SummaryAmgen beats Gilead Sciences on 14 of the 22 factors compared between the two stocks. Get Amgen News Delivered to You Automatically Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMGN vs. The Competition Export to ExcelMetricAmgenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.78B$3.12B$5.77B$8.98BDividend Yield3.24%1.57%4.78%3.85%P/E Ratio40.1330.1126.4618.82Price / Sales4.87412.67456.6780.61Price / Cash9.69183.5344.0437.47Price / Book27.703.567.634.64Net Income$4.09B-$71.72M$3.18B$245.69M7 Day Performance4.07%-2.46%-1.91%-2.66%1 Month Performance10.81%-0.25%-0.19%-2.15%1 Year Performance6.25%-12.31%16.70%12.90% Amgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMGNAmgen4.465 of 5 stars$303.01+1.7%$314.09+3.7%+6.9%$162.78B$33.42B40.1326,700Insider TradePositive NewsGILDGilead Sciences4.7808 of 5 stars$104.08-1.8%$101.33-2.6%+50.2%$129.71B$27.12B1,156.4418,000Analyst UpgradeInsider TradeOptions VolumeAnalyst RevisionPositive NewsVRTXVertex Pharmaceuticals4.1116 of 5 stars$459.00-0.8%$505.57+10.1%+15.4%$118.21B$9.87B-230.655,400Analyst DowngradeInsider TradeAnalyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.6169 of 5 stars$673.60-0.1%$973.13+44.5%-26.5%$74.02B$14.20B17.6013,450Dividend AnnouncementALNYAlnylam Pharmaceuticals4.5007 of 5 stars$256.45-3.2%$299.43+16.8%+61.9%$33.08B$1.83B-97.882,100Analyst ForecastInsider TradeBIIBBiogen4.7446 of 5 stars$137.33-0.8%$211.96+54.3%-36.4%$20.01B$9.84B12.417,570Analyst ForecastUTHRUnited Therapeutics4.3584 of 5 stars$370.58+0.0%$382.08+3.1%+64.8%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5326 of 5 stars$70.42+0.6%$75.59+7.3%+19.4%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9187 of 5 stars$64.85+0.7%$94.20+45.3%-22.9%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNBIXNeurocrine Biosciences4.9717 of 5 stars$115.02-1.6%$166.90+45.1%-7.6%$11.65B$2.36B34.961,400Analyst DowngradeBuyback AnnouncementAnalyst RevisionGap UpEXELExelixis4.6306 of 5 stars$35.00+1.5%$37.24+6.4%+77.8%$10.00B$1.83B22.441,310Analyst UpgradeInsider Trade Related Companies and Tools Related Companies GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors BMRN Competitors NBIX Competitors EXEL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMGN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMGN Stock Alerts